VenatoRx Pharmaceuticals to Present Data for its Injectable and Orally Bioavailable Beta-Lactamase Inhibitor Drug Candidates at ECCMID 2019

MALVERN, Pa.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/AMR?src=hash" target="_blank"gt;#AMRlt;/agt;–VenatoRx
Pharmaceuticals will present posters for its two development-stage
products, Cefepime/VNRX-5133 and Ceftibuten/VNRX-7145, at the 29^th European
Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be
held April 13-16, 2019 in Amsterdam, The Netherlands.

— Cefepime/VNRX-5133 —

VNRX-5133 is an injectable beta-lactamase inhibitor (BLI) that features
selective and potent in vitro activity against both serine- and
metallo-beta-lactamases, including ESBL, OXA, KPC, NDM, and VIM enzymes.
VenatoRx believes that VNRX-5133, in a fixed combination with the fourth
generation cephalosporin, cefepime, has the potential to provide a
valuable broad-spectrum treatment option to meet unmet medical need in
patients with infections due to carbapenem-resistant pathogens including
carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Pseudomonas
aeruginosa (CRPA), suspected polymicrobial infections caused by both
gram-negative and gram-positive susceptible pathogens, and engineerable
MDR bioterror pathogens such as Burkholderia spp. and Salmonella
spp. Early clinical studies of cefepime/VNRX-5133 have been completed
and VenatoRx intends to initiate Phase 3 pivotal trials during the
second quarter 2019.

This project has been funded in whole or in part with Federal funds from
the National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Department of Health and Human Services, under
Contract No. HHSN272201300019C, and The Wellcome Trust under Award No.
360G-Wellcome-101999/Z/13/Z.

VenatoRx’s presentations at ECCMID featuring Cefepime/VNRX-5133 will
take place as follows:

PS069 – New
beta-lactamase inhibitors: in vitro studies
April 14, 2019
13:30
– 14:30 CET
Paper Poster Session
Location: Paper Poster Arena

• #P1175 — Antimicrobial activity of cefepime in combination with
  VNRX-5133 against a global 2018 surveillance collection of clinical
  isolates. M. Hackel, D. Sahm.
• #P1176 — Antimicrobial activity of cefepime in combination with
  VNRX-5133 against a collection of beta-lactamase-producing
  Enterobacteriaceae. M. Hackel, D. Sahm.
• #P1177 — Activity of cefepime/VNRX-5133 and comparators against an
  Italian nationwide collection of Pseudomonas aeruginosa from
  respiratory and bloodstream infections. A. Antonelli, T. Giani, M.
  Coppi, E. Riccobono, G. Baldi, V. DiPilato, L. Xerri, G.M. Rossolini.
• #P1178 — VNRX-5133 maintains potent inhibitory activity in
  engineered NDM-1 variants with increased cefepime hydrolytic
  efficiency. M. Perilli, A. Piccirilli, B. Segatore, D. Daigle, G.
  Amicosante.
• #P1179 — Evaluation of the in vitro activity of cefepime plus
  VNRX-5133 and comparative agents against carbapenem-resistant
  Enterobacteriaceae. R. Shields, C. Jones, E. Kline, R. Mettus, C.
  Clancy, M. Nguyen, Y. Doi.

PS113 – Recent
research on the pharmacokinetics and safety of antibacterial agents
April
15, 2019
13:30 – 14:30 CET
Paper Poster Session
Location:
Paper Poster Arena

• #P1951 — Pharmacokinetics of VNRX-5133 in Combination with Cefepime
  and Metronidazole. T. Henkel, B. Geibel, J. Dowell, D. Dickerson.

OE208 – Defining
exposure, efficacy and safety of new antimicrobial agents
April
16, 2019
11:00 – 12:00 CET
Mini-oral ePoster Session
Location:
Arena 2

• #O1061— Pharmacodynamics of VNRX-5133 in combination with cefepime
  studied in an in vitro model of infection. K. Bowker, A. Noel, M.
  Attwood, A.P. MacGowan.
• #O1064 — In vivo pharmacodynamic profile of cefepime in combination
  with VNRX-5133 against serine beta-lactamase-producing Gram-negative
  bacteria in the neutropenic murine thigh infection model. K.
  Abdelraouf, S.A. Abuhussain, D. Nicolau.

— Ceftibuten/VNRX-7145 Presentations —

VNRX-7145 is an orally bioavailable BLI that in a fixed combination with
the third generation orally bioavailable cephalosporin, ceftibuten, has
the potential to rescue activity of the partner antibiotic against ESBLs
and key carbapenem-resistant Enterobacteriaceae, including those
expressing KPC and OXA carbapenemases.

This project has been funded in part with Federal funds from the
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Department of Health and Human Services, under
Contract No. HHSN272201600029C.

VenatoRx’s presentations at ECCMID featuring Ceftibuten/VNRX-7145 will
take place as follows:

PS069 – New
beta-lactamase inhibitors: in vitro studies
April 14, 2019
13:30
– 14:30 CET
Paper Poster Session
Location: Paper Poster Arena

• #P1180 — In vitro activity of the orally available
  ceftibuten/VNRX-7145 combination against a challenge set of
  Enterobacteriaceae pathogens carrying molecularly characterised
  beta-lactamase genes. R. Mendes, P. Rhomberg, A. Watters, M.
  Castanheira, R. Flamm.
• #P1181 — Selection of ceftibuten as the partner antibiotic for the
  oral beta-lactamase inhibitor VNRX-7145. J. Hamrick, C. Chatwin,
  K. John, C. Burns, L. Xerri, G. Moeck. D. Pevear
• #P1182 — Ceftibuten/VNRX-7145, an orally bioavailable
  beta-lactam/beta-lactamase inhibitor combination active against
  serine-beta-lactamase producing Enterobacteriaceae. C. Myers, D.
  Daigle, C. Burns, D. Pevear.
• #P1183 — Oral ceftibuten/VNRX-7145 shows equivalent activity in
  vitro to IV therapeutics against MDR Enterobacteriaceae. J.
  Hamrick, C. Chatwin, K. John, C. Burns, L. Xerri, G. Moeck, D. Pevear.

About VenatoRx Pharmaceuticals, Inc.

VenatoRx is a private pharmaceutical company that is focused on the
discovery and development of novel anti-infectives to treat
multi-drug-resistant bacterial infections and hard-to-treat viral
infections. Founded in 2010, VenatoRx has built a world-class in-house
R&D organization that has filed over 100 patents spanning multiple
research programs. VenatoRx has received significant funding awards from
the National Institute of Allergy and Infectious Diseases (NIAID) of the
National Institutes of Health (NIH), Wellcome Trust, CARB-X, and the
Defense Threat Reduction Agency (DTRA) as well as private equity
investments from Versant Ventures, Abingworth, and Foresite Capital.

In addition to VenatoRx’s advanced development-stage products featured
in this press release, the Company has a broad pipeline of preclinical
programs including a novel class of Penicillin-Binding Protein (PBP)
inhibitors that are impervious to beta-lactamase-driven resistance, and
novel antiviral agents targeting Hepatitis B Virus. For more
information, please visit www.venatorx.com.

Contacts

MEDIA CONTACT:
Heather Hunter
Vice President,
Communications
VenatoRx Pharmaceuticals, Inc.
[email protected]
610.644.8935
x8327